Puig S - Search Results

1

Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR.

Domingo-Domènech J, Molina R, Castel T, Montagut C, Puig S, Conill C, Martí R, Vera M, Auge JM, Malvehy J, Grau JJ, Gascon P, Mellado B. Domingo-Domènech J, et al. Among authors: puig s. Oncology. 2005;68(4-6):341-9. doi: 10.1159/000086973. Epub 2005 Jul 11. Oncology. 2005. PMID: 16020961

2

Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene.

Puig S, Ruiz A, Lázaro C, Castel T, Lynch M, Palou J, Vilalta A, Weissenbach J, Mascaro JM, Estivill X. Puig S, et al. Am J Hum Genet. 1995 Aug;57(2):395-402. Am J Hum Genet. 1995. PMID: 7668266 Free PMC article.

3

Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.

Puig S, Ruiz A, Castel T, Volpini V, Malvehy J, Cardellach F, Lynch M, Mascaro JM, Estivill X. Puig S, et al. Hum Genet. 1997 Dec;101(3):359-64. doi: 10.1007/s004390050642. Hum Genet. 1997. PMID: 9439668

4

Retention of the CDKN2A locus and low frequency of point mutations in primary and metastatic cutaneous malignant melanoma.

Ruiz A, Puig S, Lynch M, Castel T, Estivill X. Ruiz A, et al. Among authors: puig s. Int J Cancer. 1998 May 4;76(3):312-6. doi: 10.1002/(sici)1097-0215(19980504)76:3<312::aid-ijc4>3.0.co;2-y. Int J Cancer. 1998. PMID: 9579564

5

CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.

Ruiz A, Puig S, Malvehy J, Lázaro C, Lynch M, Gimenez-Arnau AM, Puig L, Sánchez-Conejo J, Estivill X, Castel T. Ruiz A, et al. Among authors: puig s, puig l. J Med Genet. 1999 Jun;36(6):490-3. J Med Genet. 1999. PMID: 10874641 Free PMC article.

6

Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases. Hospital Clinic Malignant Melanoma Group, University of Barcelona.

Puig S, Castro J, Ventura PJ, Ruiz A, Ascaso C, Malvehy J, Estivill X, Mascaro JM, Lecha M, Castel T. Puig S, et al. Melanoma Res. 2000 Jun;10(3):231-6. Melanoma Res. 2000. PMID: 10890376

7

Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.

Vilella R, Benítez D, Milà J, Lozano M, Vilana R, Pomes J, Tomas X, Costa J, Vilalta A, Malvehy J, Puig S, Mellado B, Martí R, Castel T. Vilella R, et al. Among authors: puig s. Cancer Immunol Immunother. 2004 Jul;53(7):651-8. doi: 10.1007/s00262-003-0495-3. Epub 2004 Mar 16. Cancer Immunol Immunother. 2004. PMID: 14999431 Free PMC article. Clinical Trial.

8

Dermoscopy of skin lesions in two patients with xeroderma pigmentosum.

Malvehy J, Puig S, Martí-Laborda RM. Malvehy J, et al. Among authors: puig s. Br J Dermatol. 2005 Feb;152(2):271-8. doi: 10.1111/j.1365-2133.2004.06332.x. Br J Dermatol. 2005. PMID: 15727638

9

S-100beta and MIA in advanced melanoma in relation to prognostic factors.

Auge JM, Molina R, Filella X, Bosch E, Gonzalez Cao M, Puig S, Malvehy J, Castel T, Ballesta AM. Auge JM, et al. Among authors: puig s. Anticancer Res. 2005 May-Jun;25(3A):1779-82. Anticancer Res. 2005. PMID: 16033099 Free article.

10

Dermoscopy is useful for the recognition of benign-malignant compound tumours.

Zaballos P, Llambrich A, Puig S, Malvehy J. Zaballos P, et al. Among authors: puig s. Br J Dermatol. 2005 Sep;153(3):653-6. doi: 10.1111/j.1365-2133.2005.06717.x. Br J Dermatol. 2005. PMID: 16120160 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

994 results

Search Page

Filters